• Saved

Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021 | BioSpace

Lilly Presents Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021 | BioSpace

Source : https://www.biospace.com/article/releases/lilly-presents-patient-reported-outcomes-from-the-positive-phase-3-monarche-trial-for-verzenio-at-st-gallen-virtual-congress-2021/

PRO data further support the monarchE results to date for Verzenio for the treatment of HR+, HER2- high risk early breast cancer First disclosure of patient-reported outcomes for a Phase 3 study of a CDK4 & 6 inhibitor in the adjuvant setting for HR+, HER2- early breast cancer INDIANAPOLIS, March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC).